Truist Cuts Hims & Hers Health, Inc. (HIMS) Price Target, Cites Mixed Revenue Outlook

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best Russell 2000 stocks to buy now. On August 18, Truist Securities lowered its price target on Hims & Hers from $48 to $37, while maintaining a Hold rating. Despite an 8% dip over the past week, the stock remains up 195% year-over-year, trading at $46.02.

Truist expects modest GLP-1 revenue growth in Q3 and Q4, aided by deferred revenue and the Zava acquisition, which may help meet the lower end of guidance. However, the firm flagged concerns about 2026 growth, emphasizing its revenue mix analysis over app downloads or MAU metrics.

Hims & Hers Health, Inc. (NYSE:HIMS) is a consumer-focused telehealth company. It provides personalized healthcare and wellness services through a digital platform that connects patients with licensed medical professionals. The company offers treatments across various categories, including sexual health, mental health, dermatology, and primary care.

While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Energy Stocks to Buy For the Long Term and Top 10 Industrial Stocks to Buy Amid Easing Tariff Uncertainties.

Disclosure: None. This article is originally published at Insider Monkey.